Mandatory notification regarding exercise and trade of subscription rights and trade of shares

Posted on Dec 21, 2016

Oslo, December 21, 2016 – Overview of mandatory notification regarding exercise and trade of subscription rights and trade of shares. Management and the board of directors of PCI Biotech Holding ASA (“PCI Biotech” or “the Company”) are all supportive to the share issue resolved by the extra ordinary general meeting 8 December 2016. In total […]

Successful Investigational New Drug (IND) application

Posted on Dec 14, 2016

Oslo, December 14, 2016 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, reported today that it has received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its Phase II clinical programme for fimaporfin (Amphinex®). Fimaporfin is in clinical development for inoperable bile duct cancer […]

Commencement of subscription period

Posted on Dec 14, 2016

Oslo, December 14, 2016 – As previously announced, PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) will conduct a rights issue of 10,000,000 new shares (the “Offer Shares”) in the Company (the “Rights Issue”) raising gross proceeds of NOK 70 million. The Financial Supervisory Authority of Norway has approved the prospectus dated 13 December […]